- Home
- INCY vs ASTS Comparison
INCY vs ASTS Comparison
Compare INCY & ASTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- ASTS
- Stock Information
- Founded
- INCY 1991
- ASTS 2019
- Country
- INCY United States
- ASTS United States
- Employees
- INCY N/A
- ASTS N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- ASTS Telecommunications Equipment
- Sector
- INCY Health Care
- ASTS Consumer Discretionary
- Exchange
- INCY Nasdaq
- ASTS Nasdaq
- Market Cap
- INCY 13.0B
- ASTS 13.6B
- IPO Year
- INCY 1993
- ASTS N/A
- Fundamental
- Price
- INCY $86.92
- ASTS $48.08
- Analyst Decision
- INCY Buy
- ASTS Buy
- Analyst Count
- INCY 20
- ASTS 7
- Target Price
- INCY $79.06
- ASTS $49.48
- AVG Volume (30 Days)
- INCY 1.9M
- ASTS 10.4M
- Earning Date
- INCY 07-29-2025
- ASTS 08-11-2025
- Dividend Yield
- INCY N/A
- ASTS N/A
- EPS Growth
- INCY 900.04
- ASTS N/A
- EPS
- INCY 4.37
- ASTS N/A
- Revenue
- INCY $4,584,996,000.00
- ASTS $4,892,000.00
- Revenue This Year
- INCY $13.53
- ASTS $1,331.30
- Revenue Next Year
- INCY $10.38
- ASTS $370.72
- P/E Ratio
- INCY $19.90
- ASTS N/A
- Revenue Growth
- INCY 18.87
- ASTS 249.43
- 52 Week Low
- INCY $53.56
- ASTS $17.50
- 52 Week High
- INCY $87.06
- ASTS $60.95
- Technical
- Relative Strength Index (RSI)
- INCY 80.83
- ASTS 45.97
- Support Level
- INCY $76.45
- ASTS $47.12
- Resistance Level
- INCY $79.43
- ASTS $51.95
- Average True Range (ATR)
- INCY 2.57
- ASTS 3.38
- MACD
- INCY 1.01
- ASTS -0.97
- Stochastic Oscillator
- INCY 99.13
- ASTS 25.39
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About ASTS AST SpaceMobile Inc.
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.